Opinion|Videos|August 11, 2023
Reducing Risk of Disease Progression in Patients With PV
Author(s)John Mascarenhas, MD, Joe Scandura, MD, PhD
Dr Joe Scandura discusses how he considers risk of disease progression when during therapeutic decision making for a patient with polycythemia vera.
Advertisement
Episodes in this series
Advertisement
Related to this article
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
3
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
4
AI Tools Show Early Promise Across Drug Discovery, Clinical Decision-Making in Lung Cancer
5